MYD88mutation status does not impact overall survival in Waldenström macroglobulinemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MYD88mutation status does not impact overall survival in Waldenström macroglobulinemia

Published:2017-11-17 Issue:2 Volume:93 Page:187-194
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Abeykoon Jithma P.¹^ORCID,Paludo Jonas¹²^ORCID,King Rebecca L.³,Ansell Stephen M.¹²,Gertz Morie A.¹²,LaPlant Betsy R.⁴,Halvorson Alese E.⁴,Gonsalves Wilson I.¹²^ORCID,Dingli David¹²,Fang Hong³,Rajkumar S. Vincent¹²,Lacy Martha Q.¹²,He Rong³,Kourelis Taxiarchis¹,Reeder Craig B.⁵,Novak Anne J.²,McPhail Ellen D.³,Viswanatha David S.³,Witzig Thomas E.¹²^ORCID,Go Ronald S.¹²^ORCID,Habermann Thomas M.¹²,Buadi Francis K.¹²,Dispenzieri Angela¹²,Leung Nelson¹²^ORCID,Lin Yi¹²,Thompson Carrie A.¹²,Hayman Suzanne R.¹²,Kyle Robert A.¹²,Kumar Shaji K.¹²,Kapoor Prashant¹²

Affiliation:

1. Department of Internal Medicine; Mayo Clinic; Rochester Minnesota

2. Division of Hematology; Mayo Clinic; Rochester Minnesota

3. Division of Hematopathology; Mayo Clinic; Rochester Minnesota

4. Division of Biomedical Statistics; Mayo Clinic; Rochester Minnesota

5. Division of Hematology; Mayo Clinic; Scottsdale Arizona

Funder

AbbVie

Acerta Pharma

Alnyalm

Amgen

Bristol-Myers Squibb

Celgene

Celldex

Janssen

Karyopharm Therapeutics

Merck

Millennium

Novartis

Pfizer

Prothena

Roche

Sanofi

Seattle Genetics

Spectrum Pharmaceuticals

Takeda

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24955/fullpdf

Reference45 articles.

1. New developments in the management of Waldenstrom macroglobulinemia;Abeykoon;Cancer Manag Res.,2017

2. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications;Campo;Blood.,2011

3. Diagnosis and management of Waldenstrom macroglobulinemia Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016;Kapoor;JAMA Oncol.,2017

4. Genomic organization and promoter characterization of human CXCR4 gene;Caruz;FEBS Lett.,1998

5. Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma;Ansell;Blood Cancer J.,2014

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia;Journal of Clinical Oncology;2024-07-20

2. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia;Blood;2024-04-25

3. Single‐cell analysis of MYD88^L265P and MYD88^WT Waldenström macroglobulinemia patients;HemaSphere;2024-02

4. In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation;Annals of Hematology;2023-11-11

5. New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia;Expert Review of Hematology;2023-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3